Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

por Coret, Francisco, Pérez-Miralles, Francisco C, Gascón, Francisco, Alcalá, Carmen, Navarré, Arantxa, Bernad, Ana, Boscá, Isabel, Escutia, Matilde, Gil-Perotin, Sara, Casanova, Bonaventura
Publicado 2018

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

por Muñoz, Delicias, Escartín, Antonio, Dapena, Dolores, Coret, Francisco, Fernández-Uría, Dionisio, Pérez, Domingo, Casanova, Bonaventura, Guijarro-Castro, Cristina, Munteis, Elvira, del-Campo Amigo, María, Pego, Robustiano, Calles, Carmen, García-Rey, César, Monsalve, Nuria, Sánchez-Matienzo, David
Publicado 2013

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis

por Casanova, Bonaventura, Jarque, Isidro, Gascón, Francisco, Hernández-Boluda, Juan Carlos, Pérez-Miralles, Francisco, de la Rubia, Javier, Alcalá, Carmen, Sanz, Jaime, Mallada, Javier, Cervelló, Angeles, Navarré, Arantxa, Carcelén-Gadea, María, Boscá, Isabel, Gil-Perotin, Sara, Solano, Carlos, Sanz, Miguel Angel, Coret, Francisco
Publicado 2017